Neo Cremar Co., Ltd.

Neo Cremar Co., Ltd.

KKRX:311390
1,880.00
KRW
+30.00
(+1.62%)
582.07EPS
13.34P/E
31.10BMarket Cap
Nov 18Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1,654.59
5,470.57
3,165.74
4,132.93
4,083.12
3,360.49
3,124.73
3,765.37
6,512.56
6,501.03
Basic EPS, GAAP
159.48
896
164
192
251
-230
-623
55
237
185.47
Free Cash Flow per Basic Share
-979.82
-773.42
-1,464.73
59.49
171.57
205.2
173.57
32.05
1,184.59
879.69
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
122.06
- -
Book Value per Share
1,165.07
3,211.02
5,196.63
5,421.69
5,674.01
6,000.16
4,877.33
5,633.88
5,846.3
5,912.48
Tangible Book Value per Share
1,159.39
3,206.42
5,014.56
5,247.95
5,493.91
5,955.01
4,759.38
3,185.27
3,607.27
3,778.59
Basic Weighted Avg Shares
7
4
6
7
7
8
8
11
13
13
Sales/Revenue/Turnover
12,006
21,745
19,777
29,821
29,887
26,703
24,867
40,314
81,944
81,629
Operating Margin (%)
10.26
15.02
3.36
4.22
4.58
5.32
1.12
-1.7
6.6
4.38
Depreciation Expense
210
453
1,145
1,407
1,493
1,390
1,396
3,165
7,436
7,040
Net Income, GAAP
1,157
3,562
1,025
1,385
1,837
-1,828
-4,958
589
2,982
2,329
Effective Tax Rate (%)
13.36
17.37
- -
0.08
- -
- -
- -
- -
13.44
24.77
Profit Margin (%)
9.64
16.38
5.18
4.65
6.15
-6.84
-19.94
1.46
3.64
2.85
Working Capital
11,546
12,573
21,126
22,398
20,555
9,944
16,950
56,065
65,413
73,613
LT Debt
3,763
5,991
5,679
5,600
1,583
1,350
1,161
6,813
6,387
5,486
Total Equity
8,400
23,150
37,867
39,787
41,689
47,688
38,861
143,021
146,331
149,958
Return on Invested Capital (%)
- -
12.52
- -
2.77
- -
- -
- -
- -
2.87
1.61
Return on Capital (%)
- -
17.98
- -
3.48
- -
- -
- -
- -
1.25
-0.95
Return on Common Equity (%)
- -
22.58
3.37
3.58
4.52
-4.09
-11.46
1.07
4.13
3.16

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
12,393
12,430
12,421
LT Borrowings
1,952
1,653
1,543
LT Finance Leases
4,435
4,177
3,943
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
73,756
52,710
31,098

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
85,348
89,727
94,364
Cash, Cash Equivalents & STI
46,376
51,126
46,037
Accounts Receivable, Net
12,396
11,834
13,073
Inventories
14,641
13,596
13,011
Total Current Liabilities
19,935
23,462
20,752
Payables & Accruals
- -
- -
- -
ST Debt
12,393
12,430
12,421
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
54.2%
2.31%
Free Cash Flow
- -
875.06%
4,243.35%
Net Income, GAAP
- -
59.79%
406.41%
Sales/Revenue/Turnover
- -
29.62%
103.27%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,385
6,279
5,922
22,727
40,314
2025
20,798
21,446
18,051
21,648
81,944
2026
19,084
22,845
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-187
324
-128
3.34
55
2025
94
103
81.82
-40.79
237
2026
10.67
134
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
122.06
2026
- -
- -
- -
- -
- -

Company Description

Full Time Employees
70
Sector
Consumer non-durables
Industry
Food: major diversified
Address
Seoul South Korea
IPO Date
Aug 22, 2019
Business
Neo Cremar Co., Ltd. is a South Korea-based biotechnology and functional food ingredients company that specializes in the research, development, manufacture, and distribution of microbiome-oriented functional carbohydrates, bio-peptides, and nutritional ingredients. Founded in 1999 and headquartered in Seoul, South Korea, the company serves the food, beverage, infant formula, dietary supplement, and cosmeceutical industries across domestic and global markets, including North America, Europe, Asia, and Oceania. Neo Cremar operates across functional food materials, health functional finished goods, and healthcare segments. Its product portfolio comprises prebiotic galactooligosaccharides sold under the NeoGOS brand, including high-purity and organic-certified GOS powders and syrups engineered for gut microbiome modulation, infant nutrition, and skin health; functional low-glycemic carbohydrates and sugar alternatives, including palatinose (isomaltulose) and organic fructooligosaccharides (FOS); proprietary yeast hydrolysate peptides, notably DNF-10 (Eatless), formulated for appetite regulation, satiety promotion, and metabolic weight management; specialized solubilizable food additives, including cyclodextrin formulations and soluble dietary fibers; and life care and oral hygiene products, including tapered toothbrush filaments produced through its consolidated subsidiary, BBC Co., Ltd. In recent developments, Neo Cremar has advanced its business diversification and global market reach through strategic collaborations, including a memorandum of understanding (MOU) with Taiwan-based Glac Biotech to jointly develop and distribute synergistic microbiome and probiotic formulations. The company has also expanded into the companion animal healthcare sector by initiating clinical efficacy trials for pet health functional ingredients, launched Nutrimate as a specialized functional brand for senior and healthy-aging nutrition, and accelerated the export distribution of its proprietary DNF-10 peptide across core markets in North America and Asia following expanded international health and organic certifications.